Navigation Links
EntreMed Receives Notice of NASDAQ Compliance
Date:10/15/2010

statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations240-864-2643
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... to infringe two Australian patents of B. Braun Melsungen AG ... Australia safety IV catheters manufactured by Poly ... of Australia proceeding number VID 463 ... In the detailed judgment, Multigate was found to ...
(Date:10/31/2014)... , October 30, 2014 ... announced the addition of the  "Process Validation in ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... and Risk Based Approach to Process Validation for ... Management FDA Process Validation Guidance ...
(Date:10/31/2014)... , Oct. 31, 2014 Though therapies ... technologies are expected to show an annual increase of ... value of nearly $1 billion, according to Kalorama Information,s ... from proprietary stem cell therapeutics that have gained or ... "As drug developers tackle ever more complicated ...
Breaking Medicine Technology:B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Report: Stem Cell Technologies Market Growing 2
... May 11, 2012  Amgen (NASDAQ: AMGN ) ... vice president of Research and Development at Amgen will ... Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members ... for biosimilars to establish approval standards that advance patient ...
... Mylan Inc. (Nasdaq: MYL ) today ... mg, 20 mg, 40 mg and 80 mg in ... has received marketing authorization from each country,s respective health ... is the generic version of Pfizer,s Lipitor® Tablets. This ...
Cached Medicine Technology:Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 2Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 3Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 4Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 5Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars 6Mylan Launches Generic Lipitor® in Five European Countries 2
(Date:10/31/2014)... This Method to get a ... for practitioners. , The Hypopresive (aka Hipopressive) ... and Movement specializing in physical rehabilitation. Dr. Marcel ... reeducation that traditional abdominal exercises after pregnancy increased ... etc. , The Hipopressives exercises pull back in ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... 2014 Urban Hydroponics, Inc. (OTCQB:URHY), a ... it has signed a Binding Letter of Intent (LOI) ... cultivation sector - Urban Cultivator Inc. (“Urban Cultivator”), BC ... Metal Inc. (“W3 Metal” and together with Urban Cultivator ... to the LOI and an earlier non-binding term sheet, ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
... ... tracking, performance analysis, sales and management training, announced that its non-profit organization, PrideAmerica is ... Super Bowl Hearing Mission on Wednesday, February 3rd, from noon – 4 pm at ... ...
... NASHVILLE, Tenn. , Jan. 29 HCA ... quarter and fiscal year ended December 31, 2009 . ... Company,s year-end financial and accounting procedures. , (Logo: ... these uncertain economic times," said Richard M. Bracken , ...
... , DETROIT , Jan. 29 ... M.D., Ph.D., has been named the new president and chief ... thoracic oncologist, Dr. Bepler will begin his new position ... , In addition to his chief administrative duties, Dr. ...
... , CHICAGO , Jan. 29 ... decision, four national organizations representing dentists, physicians and veterinarians ... exclude health professionals from controversial new regulation intended to ... A letter sent to FTC Chairman Jon Leibowitz ...
... facial recognition systems, study authors suggest , FRIDAY, Jan. 29 ... as long as they think the faces are odd-shaped flowers, ... researchers from Australia and France determined that bees could be ... a sweet treat for doing so. , However, this doesn,t ...
... counterfeit Viagra, study says , FRIDAY, Jan. 29 (HealthDay ... especially drugs purporting to treat erectile dysfunction, are playing Russian ... best the drugs won,t help you and at worst they ... be wasting your money or you may actually be hurting ...
Cached Medicine News:Health News:CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission 2Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 2Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 3Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 4Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 5Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 6Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 7Health News:HCA Previews Fourth Quarter and Year-End 2009 Results 8Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 3Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 4Health News:Health Professionals Petition FTC For Relief From Red Flags Rule 2Health News:Health Professionals Petition FTC For Relief From Red Flags Rule 3Health News:Fake Drugs Bought on the Web Pose Big Health Risks 2Health News:Fake Drugs Bought on the Web Pose Big Health Risks 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
Medicine Products: